Literature DB >> 33087439

C-Reactive Protein Testing for Active Tuberculosis among Inpatients without HIV in Uganda: a Diagnostic Accuracy Study.

Amanda J Meyer1,2, Emmanuel Ochom2, Patricia Turimumahoro2, Patrick Byanyima3, Ingvar Sanyu3, Rejani Lalitha4, Sylvia Kaswabuli3, Alfred Andama3,4, Nicholas D Walter5, Achilles Katamba2,6, Adithya Cattamanchi2,7,8, William Worodria4, Laurence Huang7,9, Christina Yoon7,8, J Lucian Davis10,2,11,12.   

Abstract

The objective of this prospective cross-sectional study, conducted at a national referral hospital in Kampala, Uganda, was to determine diagnostic performance of serum C-reactive protein (CRP) as a triage test for tuberculosis (TB) among HIV-seronegative inpatients. We calculated the sensitivity, specificity, positive and negative likelihood ratios, and positive and negative predictive values to determine the diagnostic performance of a CRP enzyme-linked immunosorbent assay (ELISA) (Eurolyser) in comparison to that of a reference standard of Mycobacterium tuberculosis culture on two sputum samples. We constructed receiver operating curves and reported performance in reference to the manufacturer's cutoff and also to a threshold chosen to achieve sensitivity of >90%, in accordance with the WHO's target-product profile for a triage test. Among 119 HIV-seronegative inpatients, 46 (39%) had culture-positive pulmonary TB. In reference to M. tuberculosis culture, CRP had a sensitivity of 78% (95% confidence interval [CI], 64 to 89%) and a specificity of 52% (95% CI, 40 to 64%) at the manufacturer's threshold of 10 mg/liter. At a threshold of 1.5 mg/liter, the sensitivity was 91% (95% CI, 79 to 98%) but the specificity was only 21% (95% CI, 12 to 32%). Performance did not differ when stratified by illness severity at either threshold. In conclusion, among HIV-seronegative inpatients, CRP testing performed substantially below targets for a TB triage test. Additional studies among HIV-seronegative individuals in clinics and community settings are needed to assess the utility of CRP for TB screening.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Africa; CRP; diagnosis

Year:  2020        PMID: 33087439      PMCID: PMC7771459          DOI: 10.1128/JCM.02162-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  4 in total

1.  Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study.

Authors:  Flora Martinez Figueira Moreira; Renu Verma; Paulo Cesar Pereira Dos Santos; Alessandra Leite; Andrea da Silva Santos; Rafaele Carla Pivetta de Araujo; Bruna Oliveira da Silva; Júlio Henrique Ferreira de Sá Queiroz; David H Persing; Erik Södersten; Devasena Gnanashanmugam; Purvesh Khatri; Julio Croda; Jason R Andrews
Journal:  EClinicalMedicine       Date:  2021-03-06

2.  Clinical Features and Risk Factors for Active Tuberculosis in Takayasu Arteritis: A Single-Center Case-Control Study.

Authors:  Jiawei Zhou; Ruoyu Ji; Rui Zhu; Jingya Zhou; Jing Li; Xinping Tian; Yuexin Chen; Yuehong Zheng
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

3.  Analysis of risk factors for pulmonary tuberculosis with persistent severe inflammation: An observational study.

Authors:  Masafumi Shimoda; Takashi Yoshiyama; Masao Okumura; Yoshiaki Tanaka; Kozo Morimoto; Hiroyuki Kokutou; Takeshi Osawa; Koji Furuuchi; Keiji Fujiwara; Koki Ito; Kozo Yoshimori; Ken Ohta
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

4.  Reduction of blood C-reactive protein concentration complements the resolution of sputum bacillary load in patients on anti-tuberculosis therapy.

Authors:  Khalide Azam; Celso Khosa; Sofia Viegas; Isabel Massango; Nilesh Bhatt; Ilesh Jani; Norbert Heinrich; Michael Hoelscher; Stephen H Gillespie; Andrea Rachow; Wilber Sabiiti
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.